If you have any questions about DF/HCC branding or a media inquiry please contact the DF/HCC Communications Office.
Dana-Farber/Harvard Cancer Center (DF/HCC) is a research consortium of more than 1,100 cancer researchers across five Boston academic medical institutions—Beth Israel Deaconess Medical Center, Boston Children’s Hospital, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, and Massachusetts General Hospital—and two Harvard Schools—the Harvard Medical School and the Harvard T.H. Chan School of Public Health. DF/HCC, a NCI-designated comprehensive cancer center funded through a Cancer Center Support Grant awarded by the NCI, is one of the largest cancer research consortia in the country.
DF/HCC is committed to maximizing the impact of its research for cancer patients and ultimately realizing a world without cancer. DF/HCC was founded to integrate and build upon the collective talent and resources of the Harvard cancer research community. Researchers combine their scientific strengths to create a rich, collaborative environment that transcends institutional borders.
Proper DF/HCC Attributions
If research supported by DF/HCC results in publication, please acknowledge this support by including the following in your publication(s):
We thank Dana-Farber/Harvard Cancer Center for [services/research funding/event support, etc.]. Dana-Farber/Harvard Cancer Center is supported in part by an NCI Cancer Center Support Grant # P30CA006516
Ways to add the DF/HCC logo to your website or materials:
If your institution is one of the original 7 member institutions of DF/HCC, you may add “A founding member of” or “A research partner of” atop the DF/HCC logo.
If your institution is an associate member, or a partner, then “a research partner” must be used.